Hypersensitivity can have a devastating and stressful impact on patients and their families
When a patient experiences hypersensitivity due to E. coli asparaginase treatment, it can have serious consequences beyond the impact on clinical outcomes
Hesitation to continue therapy
Hypersensitivity can be frightening to patients, family members, and staff, and can lead to concerns about continuing with the same PEG-asparaginase treatment
Halting therapy
Clinical hypersensitivity is the most common reason for patients to stop asparaginase treatment1
Risk of death
Subsequent reactions can be severe and possibly life-threatening2,3
Hypersensitivity may compromise efficacy of asparaginase therapy4
In addition to causing symptoms of a hypersensitivity reaction, anti-asparaginase antibodies can also impact the effectiveness of treatment:
- Shortened asparaginase half-life5
- Subtherapeutic asparaginase levels6
- Reduced depletion of asparagine7
- Missed asparaginase doses8
Hypersensitivity is associated with an inability to deplete asparagine7
Adapted from Tong et al, 2014.7
Newly diagnosed patients (N=89) from the DCOG ALL-10 protocol were treated with PEG-asparaginase and serum asparagine levels were measured at weeks 0, 2, 4, 14, and 24 during PEG-asparaginase therapy. This included children between 1 and 18 years of age with newly diagnosed ALL and stratified as medium-risk patients. At the start of the intensification phase, the asparagine levels were normal in almost all patients (normal range 40-80 μM).7
Hypersensitivity may lead to asparaginase treatment interruptions and decreased efficacy4,9
- Most hypersensitivity reactions occur during consolidation10
- Replacement therapy should begin as soon as clinically possible, ideally within 48 to 72 hours following a hypersensitivity reaction11
Example of standard protocol: Scheduled doses of PEG-asparaginase12
Interruptions may impact protocols for patients with high-risk B-ALL (pictured).12
Hypersensitivity that interferes with subsequent asparaginase doses could result in a prolonged time period between complete consecutive doses of asparaginase, decreasing the efficacy of ALL/LBL therapy1
Switching to an asparaginase with minimal immunologic crossreactivity can help preserve patient outcomes9,13
- Compared to those who experienced hypersensitivity and subsequently missed doses, higher risk (high-risk + slow early responders for SR) patients who switched to an Erwinia-derived asparaginase therapy due to hypersensitivity were at lower risk of relapse and had higher rates of DFS8
- Rechallenging patients can compromise their outcomes and further expose them to hypersensitivity3,14
When hypersensitivity threatens patient outcomes, consider switching
to an immunologically distinct asparaginase.
Help protect patient outcomes
RYLAZE is the only FDA-approved Erwinia asparaginase for the treatment of ALL/LBL for patients who develop hypersensitivity to E. coli asparaginase15